放射免疫疗法
分子成像
医学
靶向治疗
癌症研究
伴生诊断
放射性核素治疗
临床试验
放射性核素显像
嵌合抗原受体
免疫系统
核成像
正电子发射断层摄影术
Pet成像
光学成像
临床影像学
活检
放射治疗
免疫疗法
Spect成像
病理
肿瘤科
显像剂
分子探针
癌症影像学
医学影像学
医学物理学
核医学
生物信息学
单克隆抗体
临床实习
免疫组织化学
免疫学
作者
Baoyan Liu,Kelin Wang,Kewen He,Yong Wang
标识
DOI:10.3389/fphar.2026.1923470
摘要
B7-H3 (CD276) is broadly overexpressed across solid tumors and plays active roles in immune evasion, tumor angiogenesis, and metabolic reprogramming. As B7-H3-directed antibody-drug conjugates chimeric antigen receptor T-cell therapies, and radioimmunotherapy agents advance through clinical trials, non-invasive whole-body imaging of B7-H3 expression has become a pressing clinical need. Tissue biopsy with IHC cannot capture systemic target heterogeneity, and the recent IDeate-PanTumor01 trial found no correlation between baseline B7-H3 H-score and response to ifinatamab deruxtecan-illustrating the gap that molecular imaging must fill. This mini review surveys B7-H3-targeted imaging agents by scaffold class-antibodies, affibodies, nanobodies, and bicyclic peptides-and examines radioimmunotherapy platforms that couple PET-based dosimetry with targeted radionuclide delivery.
科研通智能强力驱动
Strongly Powered by AbleSci AI